Anti-MOG-associated demyelinating disorders: two sides of the same coin
| Autor: | Marianna Pezzella, Valentino Manzo, Sergio Ferrari, Elisa Capone, Michele Spiniello, Massimo Napolitano, Lia Allegorico, Giorgia Teresa Maniscalco, Sara Mariotto, Lidia Altomare, Gennaro Alfieri, Giovanna Servillo, Rosaria Renna, Angelo Ranieri |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Optic Neuritis Neurology Dermatology Disease Antibodies 03 medical and health sciences 0302 clinical medicine medicine Plasma exchange Humans Optic neuritis 030212 general & internal medicine Demyelinating Disorder Autoantibodies Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies business.industry Anti-MOG-associated disorders (MOGAD) General Medicine medicine.disease Oligodendrocyte Psychiatry and Mental health medicine.anatomical_structure Immunology Encephalitis Myelin-Oligodendrocyte Glycoprotein Rituximab Neurology (clinical) Neurosurgery business 030217 neurology & neurosurgery Demyelinating Diseases medicine.drug |
| Zdroj: | Neurological Sciences. 42:1531-1534 |
| ISSN: | 1590-3478 1590-1874 |
| Popis: | Anti-myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are new emerging diseases with heterogeneous course, treatment, response, and prognosis. We herein present 2 cases with antibodies to MOG, one with a cerebellar/brainstem monophasic syndrome which partially improved after treatment, and the other with an optic neuritis onset then relapsed with cortical encephalitis and presented a subsequent complete recovery. We further discuss elements possibly associated with disease heterogeneity and influencing treatment choices. MOGAD is an extremely variable disease which can relapse and accumulate disability over time. An early diagnosis and correct timely treatment is fundamental to improve clinical outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink